ROCKVILLE, Md. and BALTIMORE, May 20, 2013 /PRNewswire/ -- BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, today announced its selection of Ram Aiyar, Ph.D., M.B.A., as the first Entrepreneur-in-Residence (EIR) for BHI at the National Institutes of Health's (NIH) National Heart, Lung and Blood Institute (NHLBI). Dr. Aiyar will help advance fundamental research discoveries to new therapeutics, diagnostics and devices that can be used clinically and commercially.
"We're pleased to add Dr. Aiyar to our roster of Entrepreneurs-in-Residence," said Rich Bendis, BHI President and CEO. "He is now our third EIR – joining Todd Chappell , who is EIR at NIH, and Ken Malone , our EIR working with the University of Maryland Ventures. The growth of this program will be a benefit to BHI and our partner organizations for years to come, and will result in transitioning more early-stage biomedical technologies to commercial potential."
As the newest EIR, Dr. Aiyar will rely on his extensive experience providing guidance to life science companies in the therapeutic, diagnostic and medical device space and evaluating commercial, scientific, regulatory, and development feasibility. He will work closely with NHLBI scientific, medical, and technology transfer staff members to identify, evaluate, and support the advancement of early-stage biomedical technologies within the NHLBI mission to practical application and public benefit.
"I am excited to use my scientific, investment and operationa
|SOURCE BioHealth Innovation, Inc.|
Copyright©2012 PR Newswire.
All rights reserved